Company Overview and News

1
VNDA / Vanda Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

1
VNDA / Vanda Pharmaceuticals, Inc. S-8

2018-06-13 sec.gov
S-8 As filed with the Securities and Exchange Commission on June 13, 2018 Registration No. 333-
VNDA

1
VNDA / Vanda Pharmaceuticals, Inc. DEFA14A

2018-06-01 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

1
VNDA / Vanda Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-01 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

1
VNDA / Vanda Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-28 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

1
Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Hello and welcome to the Q1 2018, Vanda Pharmaceuticals Incorporated Earnings Conference Call. My name is Sharron. I will be your operator for today's call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference call is being recorded.
VNDA

2
VNDA / Vanda Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-05-02 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

1
VNDA / Vanda Pharmaceuticals, Inc. 8-K (Current Report)

2018-05-02 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
VNDA

87
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?

2018-05-01 zacks
Celgene Corporation (CELG - Free Report) is scheduled to report first-quarter 2018 results on May 4, before the opening bell.
CELGZ JUNO BLUE VNDA FDC TWX CELG BLUE TWC

23
What's in the Cards for Arena (ARNA) This Earnings Season?

2018-05-01 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) is expected to report first-quarter 2018 earnings in the second week of this month.
ARNA LRCX EBS VNDA TWX ADVM PF TWC

23
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?

2018-05-01 zacks
Madrigal Pharmaceuticals, Inc. (MDGL - Free Report) is expected to report first-quarter 2018 results in the second week of this month.
LRCX MDGL EBS VNDA TWX ADVM PF TWC

22
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?

2018-05-01 zacks
We expect GW Pharmaceuticals plc (GWPH - Free Report) to beat expectations when it reports its fiscal second-quarter 2018 results, expectedly on May 8.
LRCX EBS VNDA TWX ADVM PF TWC GWP

61
What's in the Cards for Ionis (IONS) This Earnings Season?

2018-05-01 zacks
Ionis Pharmaceuticals (IONS - Free Report) is scheduled to report first-quarter 2018 results on May 4, before market open.
LRCX BIIB EBS IONS VNDA TWX PF TWC AKCA

51
What's in Store for Intercept (ICPT) This Earnings Season?

2018-05-01 zacks
Intercept Pharmaceuticals, Inc. (ICPT - Free Report) is expected to report first-quarter 2018 results on May 3.
EBS VNDA ADVM ICPT

50
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

2018-04-27 zacks
Chicago, IL – April 27, 2018 - Stocks in this week’s article include: Illumina, Inc. (ILMN - Free Report) , Alarm.com Holdings, Inc. (ALRM - Free Report) , Copart, Inc. (CPRT - Free Report) and Vanda Pharmaceuticals Inc. (VNDA - Free Report) .
CPRT ASGN VNDA WDC STX ILMN CNK ALRM SGH

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 921659108